The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
REGULATORY
MHLW Approves Amgen/Astellas’ Evenity, Gilead Sciences’ Epclusa and More
The Ministry of Health, Labor and Welfare (MHLW) on January 8 approved a batch of new drugs including Amgen Astellas Biopharma’s osteoporosis treatment Evenity (romosozumab) and Gilead Sciences’ hepatitis C combo Epclusa (sofosbuvir + velpatasvir). Evenity’s approval - for the…
To read the full story
Related Article
- Japan OKs Listing of Evenity, Tarlige, Epclusa, and More on Feb. 26
February 20, 2019
- MHLW OKs Add’l Indications for Keytruda, Tecentriq, Hemlibra, and More
December 25, 2018
- Approvals for Epclusa, Keytruda’s MSI-H Indication and More Could Be Delayed into 2019
December 21, 2018
- MHLW Panel OKs Amgen Astellas’ Romosozumab, but ADHD Drug Vyvanse Put on Hold
December 4, 2018
- Keytruda’s Tumor-Agnostic Use, Gilead’s Epclusa, Wider Hemlibra Label Now in Line for Approval by Year-End
November 30, 2018
- MHLW Panel OKs Otsuka’s Alcohol Dependency Drug
November 12, 2018
- ViiV’s HIV Med Juluca Clears MHLW Panel for Quick Approval
November 12, 2018
REGULATORY
- LDP Group Proposes Higher Cap on Social Security Budgets, Category-Based Drug Pricing
May 14, 2025
- Health Minister Vows Cross-Ministry Response on Trump Executive Order
May 14, 2025
- MHLW Official Comments on PrEP Use of HIV Drugs: Diet
May 14, 2025
- LDP Project Team Proposes Review of Coverage Rules to Fuel Biosimilar Use
May 13, 2025
- Industry Renews Opposition to CEA Expansion at LDP Hearing
May 13, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…